Droplet aerodynamics, cellular uptake, and efficacy of a nebulizable corticosteroid nanosuspension are superior to a micronized dosage form

Biotechnology Progress

Volumn 28, Issue 5, 2012, Pages 1152-1159

  Britland, Stephen ^a   Finter, Wayne ^a   Chrystyn, Henry ^b   Eagland, Donald ^c   Abdelrahim, Mohamed E ^d  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

^c AGT Sciences Ltd   (United Kingdom)

^d Beni Suef University   (Egypt)

Author keywords

Asthma; Budesonide; COPD; Nanoparticle; Nebulization; Pulmicort

Indexed keywords

ASTHMA; BUDESONIDE; COPD; NEBULIZATION; PULMICORT;

AERODYNAMICS; AEROSOLS; BIOCHEMISTRY; CELL CULTURE; DRUG DELIVERY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOPARTICLES; OXYGEN; PULMONARY DISEASES; SUSPENSIONS (FLUIDS);

DRUG PRODUCTS;

BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID;

AEROSOL; ARTICLE; CELL LINE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFECT; EPITHELIUM CELL; EVALUATION; HUMAN; METABOLISM; METHODOLOGY; NEBULIZER; PARTICLE SIZE;

ADRENAL CORTEX HORMONES; AEROSOLS; BRONCHODILATOR AGENTS; BUDESONIDE; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 84867396466     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1616     Document Type: Article

References (30)

1. Huynh PN, Scott LG, Kwong KYC. Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol. Ther Clin Risk Manag. 2010; 6: 65-75.
2. Thorsson L, Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide. Respir Med. 2005; 99: 836-849.
3. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006; 533: 2-14.
4. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003; 112: S1-S40.
5. National Institute for Clinical Excellence. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over. 2008: TA138.
6. Knoch M, Keller M. The customised electronic nebulizer: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv. 2005; 2: 377-390.
7. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004; 56: 827-840.
8. Benne WD, Zeman KL, Kang WC, Schechter MS. Extrathoracic deposition of inhaled, coarse particles (4.5 μm) in children vs.adults. Ann Occup Hyg. 1997; 41: 497-502.
9. Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med. 1999; 12: 47-53.
10. Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002; 19: 189-194.
11. Abdelrahim ME, Chrystyn H. Aerodynamic characteristics of nebulized terbutaline sulphate using the next generation impactor (NGI) and CEN method. J Aerosol Med Pulm Drug Deliv. 2009; 22: 19-28.
12. Berg E, Lamb P, Ali A, Dennis J, Tservistas M, Mitchell J. Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebulizer-produced droplets. Pharmeur Sci Notes. 2008; 1: 21-26.
13. Marple V, Olson B, Santhanakrishnan K, Roberts D, Mitchell J, Hudson-Curtis B. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/minute. J Aerosol Med. 2004; 17: 335-343.
14. Berg E, Svensson JO, Asking L. Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med. 2007; 20: 97-104.
15. Nakashima T, Seki T, Matsumoto A, Miura H, Sato E, Niwano Y, Kohno M, Omura S, Takahashi Y. Generation of reactive oxygen species from conventional laboratory media. J Biosci Bioeng. 2010; 110: 304-307.
16. Wardlaw AC. Practical Statistics for Experimental Biologists, 2nd ed. Wiley and Sons, Ltd.; 2000.
17. Amani A, York P, Chrystyn H, Clark BJ, Do DQ. Determination of factors controlling the particle size in nanoemulsions using artificial neural networks. Eur J Pharm Sci. 2008; 35: 42-51.
18. Amani A, York P, Chrystyn H, Clark BJ. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. AAPS PharmSciTech. 2010; 11: 1147-1151.
19. Esmailpour N, Hogger P, Rohdewal P. Binding kinetics of budesonide to the human glucocorticoid receptor. Eur J Pharm Sci. 1998; 6: 219-223.
20. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998; 94: 557-572.
21. Henricks PAJ, Nijkamp FP. Reactive oxygen species as mediators in asthma. Pulm Pharmacol Ther. 2001; 14: 409-421.
22. Adock IM, Brown CR, Kwon O, Barnes PJ. Oxidative stress induces NF-κB DNA binding and inducible NOS mRNA in human epithelial cells. Biochem Biophys Res Commun. 1994; 199: 1518-1524.
23. Bloemen PG, Van den Tweel MC, Henricks PA, Engels F, Van de Velde MJ, Blomjous FJ, Nijkamp FP. Stimulation of both human bronchial epithelium and neutrophils is needed for maximal interactive adhesion. Am J Physiol Lung Physiol. 1996; 270: L80-L87.
24. Braga PC, Dal Sasso M, Culici M, Bianchi T, Guffanti EE. Budesonide reduces superoxide and peroxynitrate anion chemiluminescence during human neutrophil bursts. Pharmacology. 2005; 75: 179-186.
25. Dal Sasso M, Culici M, Guffani EE, Bianchi T, Fonti E, Braga PC. A combination of budesonide and the SH-metabolite I or erdosteine acts synergistically in reducing chemiluminescence during human neutrophil respiratory burst. Pharmacology. 2005; 74: 127-134.
26. Benavente CA, Jacobson EL. Niacin restriction upregulates NADPH oxidase and reactive oxygen species (ROS) in human keratinocytes. Free Radic Biol Med. 2008; 44: 527-537.
27. Bedard K, Krause K-H. The NOX family of ROS-generating NADPH Oxidases. Physiol Rev. 2007; 87: 245-313.
28. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther. 2003; 25: C28-C41.
29. Tunek P, Sjodin K, Hallstrom G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos. 1997; 25: 1311-1317.
30. Wieslander E, Deslander EW, Jarkelid L, Hjertberg E, Tunek A, Brattsand R. Pharmacologic importance of the reversible fatty acid conjugation of budesonide studies in a rat cell line in vitro. Am J Respir Cell Mol Biol. 1998; 19: 477-484.